Innovating through Technology
The BioMatrix Family of drug-eluting stents incorporate Biolimus A9™ (BA9™), an anti-restenotic drug developed specifically for use with stents and patented by Biosensors, together with a unique abluminal biodegradable polymer coating, which fully degrades into carbon dioxide and water after six to nine months as it releases BA9.
The latest additions to the BioMatrix Family are BioMatrix NeoFlex™ that features an enhanced stent delivery system, bringing exceptional performance in complex lesions and challenging anatomies and the new DCS Drug Coated Stent, BioFreedom that features a micro-structured abluminal surface, which permits the controlled release of BA9 without the use of a polymer or other carrier.